KENNETH BUCZYNSKI: Open Payments
NPI 1790704914 · OAKLAND, MD. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$330 in 17 payments from 11 companies in 2025. Trend: 2023 $444 · 2024 $538 · 2025 $330
Food & beverage: $330
| Company | Payments | Amount |
|---|---|---|
| Astellas Pharma US Inc | 3 | $68 |
| PFIZER INC. | 2 | $44 |
| AstraZeneca Pharmaceuticals LP | 2 | $38 |
| ABBVIE INC. | 2 | $35 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | 2 | $32 |
| Merck Sharp & Dohme LLC | 1 | $23 |
| Alnylam Pharmaceuticals Inc. | 1 | $22 |
| Rhythm Pharmaceuticals, Inc. | 1 | $20 |
| Bayer Healthcare Pharmaceuticals Inc. | 1 | $18 |
| Axsome Therapeutics, Inc. | 1 | $15 |
Products named: Veozah, JARDIANCE, TRUMENBA, ROTATEQ, GIVLAARI, UBRELVY, ELIQUIS, IMCIVREE.
Industry payments across MD — which companies pay providers there.
